-
FDA grants orphan drug status to Eisai's investigational compound for cutaneous T-cell lymphoma
WOODCLIFF LAKE, N.J. — Eisai Inc., announced today that the U.S. Food and Drug Administration has granted orphan drug designation to its investigational compound (E7777) for cutaneous T-cell lymphoma. E7777 is designed to have an improved purity profile and manufacturing process. It is currently in a pivotal trial intended to support its submission for approval.
-
Young consumers seek new, different condoms
There hasn't been a lot of growth in intimacy health lately, with the exception of intimacy enhancement devices, which are up 16.5% to a relatively small $26.2 million base for the 52 weeks ended June 16, according to IRI. But there is plenty of opportunity to drive growth into the category moving forward, especially with the Millennials entering the marketplace.